Chidamide Plus Nivolumab Phase III Trial Shows Median PFS of 11.7 Months in Advanced Melanoma
Start here
The global Phase III study HBI-8000-303 tested chidamide combined with nivolumab in patients with unresectable or metastatic melanoma who had not previously received PD-(L)1 inhibitor therapy. The randomized, double-blind, placebo-controlled trial showed a median progression-free survival of 11.7 months and a 27% reduction in the risk of disease progression. The results were selected as a late-breaking abstract (LBA54) at the 2026 ESMO congress, marking them as one of the meeting's highlighted presentations. The data now position the combination as a potential first-line option for advanced melanoma, though further details on overall survival, safety and regulatory filings have yet to emerge.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comChidamide Plus Nivolumab Phase III Study HBI-8000-303 Shows Median PFS of 11.7 Months in Advanced Melanoma
The global Phase III study HBI-8000-303 of chidamide plus nivolumab showed a median PFS of 11.7 months in patients with advanced melanoma, with a 27% reduction in the risk of disease progression. The results were selected as a late-breaking abstract (LBA54) at the 2026 ESMO congress. The randomized, double-blind, placebo-controlled study enrolled patients with unresectable or metastatic melanoma who had not received prior PD-(L)1 inhibitor therapy.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 28 09:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.